Aqemia prendra part à la conférence mondiale Jefferies sur la santé en 2025.

Written by Emily J. Thompson, Senior Investment Analyst

Source: Businesswire

Updated: Nov 12 2025

0mins

Source: Businesswire

Company Overview: Aqemia is a pioneering TechBio company that combines generative artificial intelligence and quantum mechanics-inspired physics to design new medications, focusing on unmet medical needs, particularly in oncology.
Leadership Participation: CEO Maximilien Levesque and VP of Finance Théa Vu-Bignand will represent Aqemia at the Jefferies Global Healthcare Conference in London from November 17-20, 2025.
Innovative Platform: The company's QEMI platform allows for the invention of therapeutic molecules in a reproducible and cost-effective manner, enabling the acceleration of innovative treatments for patients lacking effective therapeutic options.
Strategic Partnerships and Funding: Aqemia has established significant partnerships, including a $150 million multi-year alliance with Sanofi, and has raised over $100 million since its inception, with advanced preclinical programs currently in vivo optimization.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Aqemia prendra part à la conférence mondiale Jefferies sur la santé en 2025.

About the author

Top News

Ford Announces $19.5B EV Restructuring Charges

Fed Cuts Interest Rates Amid Economic Concerns

SpaceX Targets $800 Billion Valuation in Secondary Sale

U.S. Consumer Sentiment Slightly Improves in December

Related Articles

Commvault Survey Reveals Rising Data Security Concerns Among New Yorkers

V2X Secures $72 Million Contract for Gateway Mission Router Support

People Also Watch